Jul 20, 2026 8:30am EDT Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Jun 30, 2026 8:45am EDT Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
May 18, 2026 8:45am EDT Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
May 07, 2026 8:30am EDT Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Apr 23, 2026 9:00am EDT Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Apr 15, 2026 9:00am EDT Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Mar 18, 2026 8:30am EDT Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 02, 2026 8:30am EST Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
